

1    **The dimerisable Cre recombinase allows conditional genome editing in**  
2    **the mosquito stages of *Plasmodium berghei***

3

4    Priyanka Fernandes<sup>1</sup>✉, Sylvie Briquet<sup>1</sup>✉, Delphine Patarot<sup>1</sup>, Manon Loubens<sup>1</sup>,  
5    Bénédicte Hoareau-Coudert<sup>2</sup>, Olivier Silvie<sup>1\*</sup>

6

7    <sup>1</sup>Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies  
8    Infectieuses, CIMI-Paris, 75013, Paris, France

9    <sup>2</sup>Sorbonne Université, UMS PASS, Plateforme de Cytométrie de la Pitié-  
10   Salpêtrière (CyPS), 75013, Paris, France

11

12   ✉These authors contributed equally to the work

13

14

15

16   \*Corresponding author

17   Email: [olivier.silvie@inserm.fr](mailto:olivier.silvie@inserm.fr)

18

19

20

21

23 **ABSTRACT**

24 Asexual blood stages of the malaria parasite are readily amenable to genetic  
25 modification via homologous recombination, allowing functional studies of  
26 parasite genes that are not essential in this part of the life cycle. However,  
27 conventional reverse genetics cannot be applied for the functional analysis of  
28 genes that are essential during asexual blood-stage replication. Various  
29 strategies have been developed for conditional mutagenesis of *Plasmodium*,  
30 including recombinase-based gene deletion, regulatable promoters, and mRNA  
31 or protein destabilization systems. Among these, the dimerisable Cre (DiCre)  
32 recombinase system has emerged as a powerful approach for conditional gene  
33 targeting in *P. falciparum*. In this system, the bacteriophage Cre is expressed  
34 in the form of two separate, enzymatically inactive polypeptides, each fused to  
35 a different rapamycin-binding protein. Rapamycin-induced heterodimerization  
36 of the two components restores recombinase activity. We have implemented  
37 the DiCre system in the rodent malaria parasite *P. berghei*, and show that  
38 rapamycin-induced excision of floxed DNA sequences can be achieved with  
39 very high efficiency in both mammalian and mosquito parasite stages. This tool  
40 can be used to investigate the function of essential genes not only in asexual  
41 blood stages, but also in other parts of the malaria parasite life cycle.

42

44 **INTRODUCTION**

45 The life cycle of *Plasmodium* parasites is complex, and involves several stages  
46 of development and differentiation within the vertebrate host and *Anopheles*  
47 vector. In mammals, infection begins when motile forms of the parasite  
48 known as sporozoites are transmitted by infected *Anopheles* mosquitoes to the  
49 host. These sporozoites first go through an obligatory intra-hepatic step, where  
50 they multiply into thousands of merozoites that are released into the blood  
51 stream, where they begin the next round of replication within erythrocytes.  
52 Some merozoites develop into gametocytes which fuse to form a motile  
53 ookinete in the gut of the mosquito. These ookinetes encyst on the basal side  
54 of the midgut wall, where they further differentiate into sporozoites that invade  
55 the salivary glands, and are transmitted by the mosquito during the next blood-  
56 meal [1].

57 Experimental genetics have been instrumental in deciphering key aspects of  
58 the parasite biology. However, a thorough understanding of the genes that are  
59 critical for several stages of development, is lacking. The *Plasmodium* genome  
60 is haploid during the intra-erythrocytic stage of development and is thus easily  
61 amenable to genetic modification via homologous recombination. Hence most  
62 gene modification systems are adapted to targeting genes at the blood-stage  
63 of the parasite life cycle. However, as conventional reverse genetic strategies  
64 cannot be used to target genes that are essential for blood-stage replication,  
65 the functional analysis of these genes in other stages of development remains  
66 largely unexplored.

67 Various strategies have previously been developed for conditional mutagenesis  
68 in *Plasmodium*, including recombinase-based gene deletion [2], regulatable

69 promoters [3], and mRNA or protein destabilization systems [4–7]. While most  
70 of these strategies are stage-specific, others require a promoter that is  
71 expressed by distinct stages of the parasite, thus limiting the investigation of  
72 essential genes in multiple developmental stages. In recent years, the  
73 dimerisable Cre (DiCre) recombinase system has emerged as an efficient  
74 system for conditional gene knockout in *P. falciparum* and other apicomplexans  
75 [2,8]. It consists of the expression of the bacteriophage Cre in the form of two  
76 separate, enzymatically inactive polypeptides, each fused to a different  
77 rapamycin-binding protein (either FKBP12 or FRB) that heterodimerise after the  
78 addition of rapamycin [9]. Heterodimerisation of the two components in turn  
79 restores recombinase activity, leading to site-specific excision of Lox-flanked  
80 DNA sequences and rapid and efficient rapamycin-induced gene deletion [2,8].  
81 We implemented a similar approach in *P. berghei*, a rodent parasite model that  
82 is used to study malaria in the laboratory, as its life cycle can be completed by  
83 cycling between infected mice and *Anopheles* mosquitoes. We first generated  
84 a *P. berghei* parasite line that stably expresses both components of the DiCre  
85 cassette, and validated that the resulting parasite line showed no phenotypical  
86 defect as compared to the parental strain. We show that a single rapamycin  
87 dose administered to mice is sufficient to induce efficient excision of a floxed  
88 target DNA sequence *in vivo* in mice, including in transmission stages. By  
89 adapting the rapamycin treatment to mosquitoes, we also show that Cre-  
90 mediated excision can be achieved in mosquito stages, thus demonstrating the  
91 versatility and robustness of the DiCre system to inactivate genes across the  
92 parasite life cycle.

93

94 **MATERIALS AND METHODS**

95 **Ethics statement**

96 All animal work was conducted in strict accordance with the Directive  
97 2010/63/EU of the European Parliament and Council on the protection of  
98 animals used for scientific purposes. Protocols were approved by the Ethical  
99 Committee Charles Darwin N°005 (approval #7475-2016110315516522).

100

101 **Generation of plasmids for transfection**

102 *DiCre plasmid.* The DiCre plasmid was designed to replace the GFP cassette  
103 previously introduced in the *p230p* locus of *P. berghei* ANKA parasites [10] by  
104 mCherry, DiCre and TgDHFR/TS cassettes. The DiCre plasmid was generated  
105 by assembling five DNA fragments: a mCherry cassette flanked by a 800-kb 3'  
106 fragment of *P. berghei* HSP70 promoter and PbDHFR 3'UTR (DC1); a Cre59  
107 coding sequence followed by PfCAM 3'UTR (DC2); a bidirectional eEF1 $\alpha$   
108 promoter (DC3); a Cre60 coding sequence followed by the 3' UTR of PbHSP70  
109 (DC4); and a sequence corresponding to the 3' UTR of PbDHFR (DC5). All  
110 elements of the DiCre plasmid were amplified by PCR using standard PCR  
111 conditions (using the CloneAmp HiFi PCR premix) and sequentially ligated (In-  
112 Fusion HD Cloning Kit, Clontech) into an acceptor plasmid containing a  
113 TgDHFR/TS cassette flanked by two LoxP sites. The DC2 and DC4 fragments  
114 were amplified using genomic DNA from DiCre-expressing *P. falciparum*  
115 parasites (kind gift of Kai Wengelnik and Mike Blackman). The resulting plasmid  
116 sequence was verified by Sanger sequencing (Eurofins Genomics) and  
117 linearized with *Scal* and *Dra*III before transfection. The DC1 and DC5  
118 fragments served as homology regions for double homologous recombination

119 between the HSP70 promoter the PbDHFR 3' UTR sequences flanking GFP at  
120 the modified p230p locus of PbGFP parasites. All primers used to construct the  
121 DiCre plasmid are listed in Table S1.

122

123 *PbDCIII plasmid*. The PbDCIII plasmid was designed to replace the mCherry  
124 cassette of the DiCre parental line with a cassette containing two fluorescent  
125 markers, GFP and ECFP, separated by a silent intron containing a LoxN site  
126 [11]. To permit the selection of transfected parasites, we also included a human  
127 dihydrofolate reductase marker (hDHFR) downstream of the GFP cassette,  
128 followed by the 3' UTR of *P. berghei* calmodulin (CAM) gene. A 2A skip peptide  
129 was introduced between GFP and hDHFR to enable transcription of both  
130 cassettes under the control of a single HSP70 promoter. Furthermore, the GFP-  
131 2A-hDHFR-PbCAM cassette was floxed by two silent introns containing LoxN  
132 sites, as shown in **Figure 3A**. The LoxN-GFP-2A-hDHFR and LoxN-ECFP  
133 fragments were ordered as synthetic genes (Eurofins Genomics). All elements  
134 of the PbDCIII plasmid were amplified by PCR using standard PCR conditions  
135 (using the CloneAmp HiFi PCR premix) and sequentially ligated into the *SphI*-  
136 *Sall* restriction sites of a pUC18 vector (In-Fusion HD Cloning Kit, Clontech).  
137 The resulting plasmid sequence was verified by Sanger sequencing (Eurofins  
138 Genomics) and linearized with *NarI* before transfection. All primers used to  
139 construct the GFP-ECFP plasmid are listed in Table S1.

140

#### 141 **Experimental animals, parasites and cell lines**

142 Female SWISS mice (6–8 weeks old, from Janvier Labs) were used for all  
143 routine parasite infections. Parasite lines were maintained in mice through

144 intraperitoneal injections of frozen parasite stocks and transmitted to *Anopheles*  
145 *stephensi* mosquitoes for experimental purposes. *P. berghei* sporozoites were  
146 isolated from infected female *Anopheles* mosquitoes and intravenously injected  
147 into C57BL/6J mice (female, 4-6 weeks old, Janvier Labs). A drop of blood from  
148 the tail was collected in 1ml PBS daily and used to monitor the parasitaemia by  
149 flow cytometry.

150 For parasite transfection, schizonts purified from an overnight culture of PbGFP  
151 or PbDiCre parasites were transfected with 5–10 µg of linearized plasmid by  
152 electroporation using the AMAXA Nucleofector device (program U033), as  
153 previously described [12], and immediately injected intravenously into the tail  
154 vein of SWISS mice. To permit the selection of resistant transgenic parasites,  
155 pyrimethamine (35 mg/L) was added to the drinking water and administered to  
156 mice, one day after transfection. The parasitaemia was monitored daily by flow  
157 cytometry and the mice sacrificed at a parasitaemia of 2-3%. The mice were  
158 bled and the infected blood collected for preparation of frozen stocks and  
159 isolation of parasites for genomic DNA extraction.

160 Pure transgenic parasite populations were isolated by flow cytometry-assisted  
161 sorting of mCherry or GFP-expressing blood stage parasites on a FACSaria II  
162 (Becton-Dickinson), as described [10]. Mice were injected intraperitoneally with  
163 frozen parasite stocks and monitored until the parasitaemia was between 0.1  
164 and 1%. On the day of sorting, one drop of blood from the tail was collected in  
165 1 ml PBS and used for sorting of 100 pRBCs which were recovered in 200 µl  
166 RPMI +20% foetal calf serum (FCS), and then injected intravenously into two  
167 mice (100 µl each). The mice were sacrificed at a parasitaemia of 2-3% and the  
168 blood recovered for preparation of frozen stocks and genotyping.

169 *Anopheles stephensi* mosquitoes were reared at 24-26°C with 80 %  
170 humidity and permitted to feed on infected mice that were anaesthetised, using  
171 standard methods of mosquito infection as previously described [13]. Post-  
172 feeding, *P. berghei*-infected mosquitoes were kept at 21°C and fed on a 10%  
173 sucrose solution. Salivary gland sporozoites were collected between 21 and 28  
174 days post-feeding from infected mosquitoes, by hand dissection and  
175 homogenisation of isolated salivary glands in complete DMEM (DMEM  
176 supplemented with 10% FCS, 1% Penicillin-Streptomycin and 1% L-  
177 Glutamine).

178 HepG2 cells (ATCC HB-8065) were cultured in DMEM supplemented  
179 with 10% FCS, 1% Penicillin-Streptomycin and 1% L-Glutamine as previously  
180 described [14].

181

## 182 **Rapamycin treatment**

183 DiCre recombinase mediated excision of targeted DNA sequences *in vivo* was  
184 achieved by oral administration of 200 µg Rapamycin (1mg/ml stock,  
185 Rapamune, Pfizer) to mice, 24 hours prior to transmission to mosquitoes. In  
186 order to achieve excision in the mosquito stages, 10 µg rapamycin (1 mg/ml  
187 stock solution in DMSO, Sigma-Aldrich) was added to 10 ml 10% sucrose  
188 solution and used to feed mosquitoes. The rapamycin dose was refreshed  
189 every alternate day along with the sucrose solution.

190

## 191 **Genotyping PCR**

192 Infected mice were sacrificed at a parasitaemia of 2-3% and the infected blood  
193 collected and passed through a CF11 column (Whatman) to deplete

194 leucocytes. The RBCs collected were then centrifuged and lysed with 0.2%  
195 saponin (Sigma) to recover parasite material for genomic DNA isolation using  
196 a kit (Qiagen DNA Easy Blood and Tissue Kit), according to the manufacturer's  
197 instructions. Specific PCR primers were designed to check for wild-type and  
198 recombined loci and are listed in Table S2. All PCR reactions were carried out  
199 using Recombinant Taq DNA Polymerase (5U/μl from Thermo Scientific) and  
200 standard PCR cycling conditions.

201

202 ***In vitro infections, immunofluorescence assays and microscopy***

203 *Infection of hepatocytes.* HepG2 cells were seeded in collagen-coated culture  
204 plates, at a density of 30,000 cells/well in a 96-well plate for flow cytometry  
205 analysis or 100,000 cells/well in 8 well μ-slide (IBIDI) for immunofluorescence  
206 assays, 24 hours prior to infection with sporozoites. On the day of infection, the  
207 culture medium in the wells was refreshed with complete DMEM, followed by  
208 the addition of 10,000 sporozoites and incubation for 3 hours at 37°C. After 3  
209 hours, the wells were washed twice with complete DMEM and then incubated  
210 for another 24-48 hours at 37°C and 5% CO<sub>2</sub>.

211 For quantification of EEF numbers, the cells were trypsinized after two washes  
212 with PBS, followed by addition of complete DMEM and one round of  
213 centrifugation. After discarding the supernatant, the cells were either directly  
214 re-suspended in FACS buffer (PBS + 3% FCS) for flow cytometry, or fixed with  
215 2% PFA for 10 minutes, subsequently washed once with PBS and then re-  
216 suspended in PBS. Cells were then analyzed on a Guava EasyCyte 6/2L bench  
217 cytometer equipped with 488 nm and 532 nm lasers (Millipore).

218 *Immunofluorescence assays.* For immunofluorescence assays, the cells were

219 washed twice with PBS, then fixed with 4% PFA for 10 minutes followed by two  
220 washes with PBS, quenching with glycine 0,1 M for 5 minutes, permeabilization  
221 with 1% Triton X-100 for 5 minutes before washes with PBS and blocking in  
222 PBS with 3% bovine serum albumin (BSA). Cells were then incubated for 1h  
223 with goat anti-UIS4 primary antibody (1:500, Sicgen), followed by donkey anti-  
224 goat Alexa Fluor 594 or Alexa Fluor 488 secondary antibody (1:1000, Life  
225 Technologies).

226 *Fluorescence microscopy.* Live samples such as blood-stages, midguts and  
227 salivary glands from infected mosquitoes, were mounted in PBS and visualised  
228 live using a fluorescence microscope (Zeiss Axio Observer.Z1 fluorescence  
229 microscope equipped with a LD Plan-Neofluar 403/0.6 Corr Ph2 M27  
230 objective). Due to spectral overlap between GFP and CFP channels, we set the  
231 exposure time according to the positive control and maintained the same  
232 exposure for both excised and non-excised parasites, in order to allow  
233 comparisons. All images were processed with ImageJ for adjustment of  
234 contrast.

235

236 **RESULTS**

237 **Generation of a DiCre-expressing *P. berghei* line**

238 To evaluate the DiCre system in *P. berghei*, we first generated a parasite line  
239 that stably and constitutively expresses both components of the Cre enzyme.  
240 We assembled a construct encoding the N-terminal Cre 59 (residues Thr19-  
241 Asn59) and C-terminal Cre 60 (Asn60-Asp343) portions of the Cre fused at their  
242 N-terminus to FKBP12 and FRB, respectively (**Figure 1A**). The two  
243 components were placed under control of the constitutive bidirectional promoter  
244 eEF1alpha, and followed by the 3' untranslated region (UTR) from PfCAM and  
245 PbHSP70, respectively. In addition, the construct contained a mCherry  
246 cassette under the control of an inactive truncated fragment of HSP70  
247 promoter, and a TgDHFR/TS pyrimethamine resistance cassette. The  
248 TgDHFR/TS cassette was flanked by two LoxP sites, to allow Cre-mediated  
249 excision and production of drug selectable marker-free parasites (**Figure 1A**).  
250 A sequence corresponding to the 3' UTR of PbDHFR was included at the end  
251 of the construct, for homologous recombination at the modified *p230p* locus of  
252 GFP-expressing *P. berghei* ANKA parasites (PbGFP) [10] (**Figure 1A**).  
253 Following transfection of PbGFP parasites, integration of the construct by  
254 double homologous recombination resulted in the replacement of GFP by  
255 mCherry and reconstitution of a functional HSP70 promoter to drive mCherry  
256 expression, along with insertion of the DiCre and TgDHFR/TS cassettes.  
257 Transfected parasites were selected with pyrimethamine and mCherry-positive  
258 parasites were sorted by FACS. The resulting parasite population was exposed  
259 to a single dose of rapamycin that was administered orally to mice. This  
260 treatment resulted in excision of the TgDHFR/TS cassette, as demonstrated by

261 PCR genotyping (**Figure 1B**). Cloning by limiting dilution resulted in the final  
262 selectable-marker free mCherry-expressing PbDiCre parasite line.

263

264 **PbDiCre parasites progress normally across the parasite life cycle**

265 To exclude any interference of the DiCre cassette with parasite life cycle  
266 progression, we examined if these parasites could be transmitted to  
267 mosquitoes and back to mice. PbDiCre parasites formed oocysts in the midgut  
268 of infected mosquitoes and developed into sporozoites that colonized the insect  
269 salivary glands (**Figure 2A**). Similar numbers of salivary gland sporozoites  
270 were recovered from mosquitoes infected with PbDiCre and parental PbGFP  
271 parasites (**Figure 2B**), confirming that PbDiCre parasites develop normally in  
272 the mosquito. In addition, when incubated with a monolayer of HepG2 cells,  
273 PbDiCre sporozoites formed similar numbers of exo-erythrocytic forms (EEFs)  
274 as PbGFP parasites (**Figure 2C**). Liver stage development of PbDiCre  
275 parasites was comparable to PbGFP, as evidenced by EEF size (**Figure 2D**)  
276 and formation of a UIS4-labeled PVM (**Figure 2E**). Finally, we injected PbDiCre  
277 and PbGFP sporozoites into C57BL/6J mice and observed no difference in  
278 either pre-patency or blood-stage parasitaemia between PbGFP- and PbDiCre-  
279 infected mice (**Figure 2F**), showing that PbDiCre parasites are capable of  
280 completing the parasite life cycle, similarly to the parental PbGFP parasites.  
281 In summary, these results confirmed that parasites constitutively expressing the  
282 DiCre cassette progress normally through the parasite life cycle, and can thus  
283 be used as a parental strain to target genes of interest.

284

285 **Exposure to rapamycin during the mammalian blood stages is efficient to**  
286 **generate recombined mosquito stages**

287 In order to assess the efficacy and robustness of the DiCre system to target  
288 genes of interest during parasite transmission to the mosquito, we designed a  
289 reporter construct that allows a simple assessment of site-specific rapamycin-  
290 induced DNA excision, using fluorescent markers. The designed construct  
291 replaced the endogenous mCherry cassette in PbDiCre parasites with a gene  
292 sequence comprised of GFP-2A-hDHFR-PbCAMutr flanked by LoxN sites, and  
293 placed under the inactive truncated fragment of HSP70 promoter (**Figure 3A**).  
294 An additional eCFP cassette lacking a promoter was inserted downstream of  
295 the second LoxN site (**Figure 3A**) thereby permitting selective expression of  
296 GFP or CFP before or after rapamycin-induced excision, respectively. Proper  
297 integration of the construct was confirmed by genotyping PCR (**Figure 3B**),  
298 resulting in a PbDCIII parasite line that provided us with a suitable tool to  
299 visually monitor rapamycin-induced excision in all developmental stages of the  
300 parasite.

301 In order to verify that exposure of blood-stages to rapamycin results in efficient  
302 gene excision, we infected mice with PbDCIII parasitised red blood cells  
303 (pRBCs) and treated them with one dose of rapamycin. Untreated mice were  
304 used as controls. At 48h post-treatment, direct examination by fluorescence  
305 microscopy confirmed the presence of CFP-positive (CFP+) parasites in the  
306 blood of rapamycin-treated mice (**Figure 4A**), while only GFP-positive (GFP+)  
307 parasites were observed in untreated mice, suggesting that gene excision in  
308 blood-stages was very efficient after rapamycin treatment. Although genotyping  
309 PCR confirmed complete excision in rapamycin-treated PbDCIII parasites,

310 excision bands could also be amplified by PCR in untreated PbDCIII parasites  
311 (**Figure 4B**), suggesting some level of activity of the Cre in the absence of  
312 rapamycin.

313 In the next step, we evaluated if DNA excision could also be induced in sexually  
314 committed parasites/gametocytes. Mice infected with PbDCIII parasites were  
315 administered rapamycin 24 hours prior to transmission to mosquitoes (**Figure**  
316 **5A**), following which infection and development of both treated and untreated  
317 parasites in the mosquito was monitored by fluorescence microscopy. We  
318 predominantly observed CFP+ oocysts and salivary gland sporozoites in  
319 mosquitoes infected with rapamycin-treated PbDCIII parasites, showing that  
320 one dose of rapamycin is sufficient to induce efficient excision in transmission  
321 stages (**Figure 5B**).

322

323 **Exposure of mosquito stages to rapamycin allows gene deletion in**  
324 **sporozoites**

325 Due to optimal activity of the Cre enzyme at 37 °C, the DiCre system has  
326 consistently been used to investigate the function of genes in *Plasmodium*  
327 blood-stages, but lacks applicability when it comes to studying the function of  
328 genes involved in ookinete formation or establishment of infection in the insect  
329 vector. In order to overcome this drawback, we tested if exposure to rapamycin  
330 of infected mosquitoes, instead of blood-stages, would result in efficient DNA  
331 excision. For this purpose, we fed PbDCIII-infected mosquitoes on a sucrose  
332 solution containing 1 µg/ml rapamycin, for two weeks, starting at day 5 post-  
333 transmission (**Figure 6A**). Interestingly, both oocysts and salivary glands  
334 isolated from treated mosquitoes were CFP+, showing that DiCre-mediated

335 DNA excision can also be induced by treating mosquitoes with rapamycin  
336 (**Figure 6B**). In these experiments, rapamycin exposure during parasite  
337 development in the mosquito was associated with a reduction of the number of  
338 salivary gland sporozoites (**Figure 6C**). However, a similar reduction was  
339 observed when rapamycin was administered to mice prior to mosquito blood  
340 feeding (**Figure 6C**). With both protocols, sporozoites remained infectious to  
341 HepG2 cells cultures (**Figure 6D**), and both rapamycin treatment regimens  
342 resulted in almost complete parasite DNA recombination as revealed by the  
343 switch from GFP to CFP expression (**Figure 6E**).  
344 Overall, these results showed that the DiCre system can be used to target  
345 genes in different developmental stages both in the mammalian host and in the  
346 mosquito vector.

347

348

349 **DISCUSSION**

350 In spite of numerous advances in gene editing technologies that are  
351 currently available to investigate the function of *Plasmodium* genes, the role of  
352 blood-stage essential genes in pre-erythrocytic developmental stages remains  
353 poorly explored. We implemented the DiCre system in *P. berghei* parasites and  
354 demonstrate how the system can be used to conditionally delete genes in *P.*  
355 *berghei* mosquito stages. We first generated a marker-free fluorescent parasite  
356 line in *P. berghei*, which constitutively expresses both components of the  
357 dimerisable Cre recombinase [9], by introducing components of the DiCre along  
358 with an mCherry cassette into a non-essential P230p locus [15]. Asexual  
359 development, sporogony in the mosquito, sporozoite infectivity in mice and EEF  
360 development *in vitro* were comparable to a reference PbGFP line [10], showing  
361 that the components of the DiCre did not interfere with parasite development or  
362 transmission. We then confirmed the integrity of the Cre components in  
363 inducing excision after rapamycin treatment, using the PbDCIII reporter line.  
364 The data obtained with the PbDCIII parasite line not only validated the activity  
365 of the Cre enzyme in PbDiCre, but also confirmed that a single dose of  
366 rapamycin was sufficient to induce close to 100% excision in blood-stages,  
367 consistent with previously published data [2,16]. Excision events were also  
368 noted in untreated PbDCIII parasites by PCR and in a minor proportion of  
369 oocysts and sporozoites, suggesting some leakiness in a minor proportion of  
370 parasites. Alternatively, we cannot exclude that co-housing of untreated and  
371 rapamycin-treated mice may result in the exposure of untreated mice to  
372 rapamycin excreted in the faeces of treated mice. Nevertheless, rapamycin-  
373 induced DNA recombination in gametocytes was very efficient as observed by

374 the lack of GFP+ oocysts in the mosquito, suggesting that targeted deletion of  
375 blood-stage essential genes can successfully be achieved in sexual stages.

376 A recent study used a *P. falciparum* NF54 DiCre parasite line to generate  
377 conditional knockouts of AMA1 and FIKK7.1 genes, and reported a significant  
378 reduction in oocyst numbers after transmission of rapamycin treated parasites  
379 to mosquitoes [17]. The authors speculated that treatment with rapamycin was  
380 mainly responsible for the reduction they observed. In agreement with these  
381 observations, we observed a reduction of salivary gland sporozoite numbers  
382 after rapamycin treatment in the DCIII parasite line. In light of these findings,  
383 we sought to circumvent the effects of rapamycin on oocyst formation by  
384 treating mosquitoes with rapamycin instead of blood-stages. Mosquitoes  
385 infected with untreated PbDCIII parasites were fed with rapamycin 5 days after  
386 the blood-meal, to avoid any effects on ookinetes and the formation of oocysts.  
387 However, a similar reduction of the number of salivary gland sporozoites was  
388 observed irrespective of the rapamycin treatment regimen. This detrimental  
389 effect could be due to inhibition of the target of rapamycin (TOR) pathway,  
390 which is known to play a role in nutritional sensing in the mosquito [18], and  
391 may participate in oocyst formation and/or development.

392 When rapamycin was administered to infected mosquitoes, we observed  
393 highly efficient excision of the GFP in PbDCIII parasites, and we only observed  
394 excised CFP+ EEFs in infected hepatocytes. Thus, rapamycin treatment can  
395 successfully be adapted to different stages in the mosquito, such as treatment  
396 of midgut sporozoites prior to salivary gland invasion or treatment of salivary  
397 gland sporozoites before hepatocyte invasion, although we predict that the  
398 percentage of excision might vary with shorter duration times.

399 In summary, we generated a fluorescent PbDiCre line and show that it  
400 can be used to investigate the function of essential blood-stage genes in  
401 mosquito stages. By treating parasites with rapamycin in the blood or in the  
402 mosquito, we demonstrate the versatility of the DiCre system in targeting genes  
403 of interest at multiple stages of development. Overall, our study introduces a  
404 new robust and versatile methodology to conditionally delete genes in different  
405 stages of *Plasmodium* parasites, which should help deciphering the function of  
406 essential genes across the parasite life cycle.

407

408

409

410

411 **ACKNOWLEDGMENTS**

412 The authors would like to thank Jean-François Franetich, Maurel Tefit, Mariem  
413 Choura and Thierry Houpert for rearing of mosquitoes. DNA encoding the Cre  
414 elements was a kind gift from Kai Wengelnik and Mike Blackman. The research  
415 leading to these results has received funding from the Laboratoire d'Excellence  
416 ParaFrap (ANR-11-LABX-0024), and the Agence Nationale de la Recherche  
417 (ANR-16-CE15-0004 and ANR-16-CE15-0010). ML was supported by a  
418 'DIM1Health' doctoral fellowship awarded by the Conseil Régional d'Ile-de-  
419 France.

420

421

422

423

424 **FIGURE LEGENDS**

425 **Figure 1. Generation of DiCre-expressing *P. berghei* parasites**

426 **A.** Replacement strategy to modify the PbGFP locus for DiCre expression. The  
427 DiCre plasmid, containing the two Cre components in addition to a mCherry  
428 cassette and a TgDHFR/TS pyrimethamine resistance cassette, was integrated  
429 into a pre-modified P230p locus in *P.berghei*, where the P230p gene was  
430 previously replaced by a GFP cassette [10]. Following parasite transfection and  
431 selection with pyrimethamine, mCherry+ parasites were sorted by flow  
432 cytometry to exclude any residual GFP+ population. Genotyping primers and  
433 expected PCR fragments are indicated by arrows and lines, respectively. **B.**  
434 PCR analysis of genomic DNA isolated from parental PbGFP, pyrimethamine-  
435 selected (pyr) and rapamycin-treated (rapa) PbDiCre parasites. Confirmation  
436 of the predicted recombination events was achieved with primer combinations  
437 specific for WT, 5' or 3' integration. The TgDHFR primer combination was used  
438 to confirm the loss of the TgDHFR/TS cassette following rapamycin treatment.

439

440 **Figure 2. PbDiCre parasites show no defect in mosquito and liver stages**

441 **A.** Fluorescence microscopy imaging of unfixed midgut oocysts and salivary  
442 glands from PbDiCre-infected mosquitoes. Scale bar, 100  $\mu$ m for the midguts  
443 and salivary glands, and 10  $\mu$ m for the magnified images. **B.** Comparison of  
444 sporozoite numbers isolated from salivary glands of female mosquitoes  
445 infected with PbGFP or PbDiCre parasites. Data shown are mean +/- SD of  
446 three independent experiments. **C.** Quantification of EEFs in HepG2 cell  
447 cultures infected with PbGFP or PbDiCre sporozoites. Data shown are mean  
448 +/- SD of two independent experiments. **D.** Quantification of EEF size (area) in

449 HepG2 cell cultures infected with PbGFP or PbDiCre sporozoites. Data shown  
450 are mean +/- SD of two independent experiments. **E.** Images of PbGFP and  
451 PbDiCre EEFs in HepG2 infected cell cultures, 48 hours post-infection. Scale  
452 bar, 10  $\mu$ m. **F.** Comparison of parasite development *in vivo* post-sporozoite  
453 injection. C57BL6/J mice (n = 5) were injected intravenously with  $1 \times 10^4$   
454 PbGFP or PbDiCre sporozoites. Parasitemia was then followed daily by FACS.  
455 The data shown are mean +/- SEM of 5 mice per group.

456

457 **Figure 3. Generation of a PbDCIII reporter line to monitor Cre activity**

458 **A.** Replacement strategy to modify the mCherry locus in PbDiCre parasites and  
459 generate the PbDCIII parasite line. The DCIII construct contains a GFP-hDHFR  
460 cassette flanked by LoxN sites, and followed by a CFP cassette. Integration of  
461 the construct results in GFP expression instead of mCherry. Following  
462 rapamycin treatment, Cre-mediated recombination results in excision of the  
463 GFP cassette and expression of CFP. Genotyping primers and expected PCR  
464 fragments are indicated by arrows and lines, respectively. **B.** PCR analysis of  
465 genomic DNA isolated from parental PbDiCre, pyrimethamine-selected (pyr)  
466 and rapamycin-treated (rapa) PbDCIII parasites. Confirmation of the predicted  
467 recombination events was achieved with primer combinations specific for 5' and  
468 3' integration.

469

470 **Figure 4. Exposure to rapamycin during the mammalian blood stages**

471 **A.** Fluorescence microscopy of unfixed blood stages in the parental PbDiCre  
472 parasites (upper panels) and in PbDCIII parasites before (middle panels) and  
473 after (lower panels) rapamycin treatment. Scale bar, 10  $\mu$ m. **B.** PCR analysis

474 of genomic DNA isolated from parental PbDiCre, pyrimethamine-selected (pyr)  
475 and rapamycin-treated (rapa) PbDCIII parasites, using primer combinations  
476 specific for non-excised or excised locus. A band corresponding to a non-  
477 excised locus can be amplified with the “excised” primer combination and is  
478 indicated with an asterisk.

479

480 **Figure 5. Rapamycin-mediated DNA recombination in sexual blood stages**

481 **A.** Illustration of the rapamycin treatment protocol applied to sexually committed  
482 blood stages prior transmission to mosquitoes. **B.** Fluorescence microscopy of  
483 unfixed midguts and salivary glands isolated from PbDCIII-infected mosquitoes  
484 parasites, before (-rapamycin) or after blood-stage rapamycin treatment (+  
485 rapamycin BS). Scale bar, 200  $\mu$ m for midguts and 100  $\mu$ m for the salivary  
486 glands.

487

488 **Figure 6. Rapamycin-mediated DNA recombination in mosquito stages**

489 **A.** Illustration of the rapamycin treatment protocol applied to infected  
490 mosquitoes. **B.** Fluorescence microscopy of unfixed midguts and salivary  
491 glands isolated from PbDCIII-infected rapamycin-treated mosquitoes. Scale  
492 bar, 200  $\mu$ m for midguts, and 100  $\mu$ m for the salivary glands. **C.** Quantification  
493 of salivary gland sporozoites in mosquitoes infected with the PbDCIII parasites,  
494 after rapamycin exposure of mice (BS) or mosquitoes (mos) in comparison to  
495 the untreated parasites. Results shown are mean+/- SD of two independent  
496 experiments. **E.** Quantification of infected cells in HepG2 cell cultures infected  
497 with the PbDCIII parasite line, after rapamycin exposure of mice (BS) or  
498 mosquitoes (mos) in comparison to untreated control. Results shown are

499 mean+/- SD of five technical replicates and are representative of two  
500 independent experiments. **F.** Quantification of excised CFP+ and non-excised  
501 GFP+ EEFs *in vitro* in infected HepG2 cell cultures, as determined by FACS.  
502 Results shown are mean+/- SD of five technical replicates and are  
503 representative of two independent experiments.

504

505

506

507 **REFERENCES**

508 1. Bannister L, Mitchell G. The ins, outs and roundabouts of malaria.  
509 Trends in Parasitology. 2003. doi:10.1016/S1471-4922(03)00086-2

510 2. Collins CR, Das S, Wong EH, Andenmatten N, Hackett F, Herman JP,  
511 et al. Robust inducible Cre recombinase activity in the human malaria  
512 parasite *Plasmodium falciparum* enables efficient gene deletion within a  
513 single asexual erythrocytic growth cycle Division of Parasitology , MRC  
514 National Institute for Me. Mol Microbiol. 2013;88: 2–5.  
515 doi:10.1111/mmi.12206

516 3. Meissner M, Krejany E, Gilson PR, De Koning-Ward TF, Soldati D,  
517 Crabb BS. Tetracycline analogue-regulated transgene expression in  
518 *Plasmodium falciparum* blood stages using *Toxoplasma gondii*  
519 transactivators. Proc Natl Acad Sci U S A. 2005;102.  
520 doi:10.1073/pnas.0500112102

521 4. Pino P, Sebastian S, Kim EA, Bush E, Brochet M, Volkmann K, et al. A  
522 tetracycline-repressible transactivator system to study essential genes  
523 in malaria parasites. Cell Host Microbe. 2012;12: 824–34.  
524 doi:10.1016/j.chom.2012.10.016

525 5. Agop-Nersesian C, Pfahler J, Lanzer M, Meissner M. Functional  
526 expression of ribozymes in Apicomplexa: Towards exogenous control of  
527 gene expression by inducible RNA-cleavage. Int J Parasitol. 2008;38:  
528 673–681. doi:10.1016/j.ijpara.2007.10.015

529 6. Prommano P, Uthaipibull C, Wongsombat C, Kamchonwongpaisan S,  
530 Yuthavong Y, Knuepfer E, et al. Inducible Knockdown of *Plasmodium*  
531 Gene Expression Using the *glmS* Ribozyme. PLoS One. 2013;8.

532 doi:10.1371/journal.pone.0073783

533 7. Armstrong CM, Goldberg DE. An FKBP destabilization domain  
534 modulates protein levels in *Plasmodium falciparum*. *Nat Methods*.  
535 2007;4: 1007–1009. doi:10.1038/nmeth1132

536 8. Andenmatten N, Egarter S, Jackson AJ, Jullien N, Herman J-P,  
537 Meissner M. Conditional genome engineering in *Toxoplasma gondii*  
538 uncovers alternative invasion mechanisms. *Nat Methods*. 2012;10:  
539 125–127. doi:10.1038/nmeth.2301

540 9. Jullien N. Regulation of Cre recombinase by ligand-induced  
541 complementation of inactive fragments. *Nucleic Acids Res*. 2003;31:  
542 131e – 131. doi:10.1093/nar/gng131

543 10. Manzoni G, Briquet S, Risco-Castillo V, Gaultier C, Topçu S, Ivănescu  
544 ML, et al. A rapid and robust selection procedure for generating drug-  
545 selectable marker-free recombinant malaria parasites. *Sci Rep*.  
546 2014;4:4760: 1–10. doi:10.1038/srep04760

547 11. Jones ML, Das S, Belda H, Collins CR, Blackman MJ, Treeck M. A  
548 versatile strategy for rapid conditional genome engineering using loxP  
549 sites in a small synthetic intron in *Plasmodium falciparum*. *Sci Rep*.  
550 2016;6. doi:10.1038/srep21800

551 12. Janse CJ, Ramesar J, Waters AP. High-efficiency transfection and drug  
552 selection of genetically transformed blood stages of the rodent malaria  
553 parasite *Plasmodium berghei*. *Nat Protoc*. 2006;1: 346–356.  
554 doi:10.1038/nprot.2006.53

555 13. Ramakrishnan C, Delves MJ, Lal K, Blagborough AM, Butcher G, Baker  
556 KW, et al. Laboratory maintenance of rodent malaria parasites. *Methods*

557 Mol Biol. 2013;923: 51–72. doi:10.1007/978-1-62703-026-7\_5

558 14. Silvie O, Franetich JF, Boucheix C, Rubinstein E, Mazier D. Alternative  
559 invasion pathways for *Plasmodium berghei* sporozoites. *Int J Parasitol.*  
560 2007;37: 173–182. Available:  
561 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&edoftp=Citation&list\\_uids=17112526](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&edoftp=Citation&list_uids=17112526)

562 15. van Dijk MR, van Schaijk BCL, Khan SM, van Dooren MW, Ramesar J,  
563 Kaczanowski S, et al. Three members of the 6-cys protein family of  
564 *Plasmodium* play a role in gamete fertility. *PLoS Pathog.* 2010;6:  
565 e1000853. doi:10.1371/journal.ppat.1000853

566 16. Kent RS, Modrzynska KK, Cameron R, Philip N, Billker O, Waters AP.  
567 Inducible developmental reprogramming redefines commitment to  
568 sexual development in the malaria parasite *Plasmodium berghei*.  
569 *Nature Microbiology.* 2018. doi:10.1038/s41564-018-0223-6

570 17. Tibúrcio M, Yang ASP, Yahata K, Suárez-Cortés P, Belda H,  
571 Baumgarten S, et al. A Novel Tool for the Generation of Conditional  
572 Knockouts To Study Gene Function across the *Plasmodium falciparum*  
573 Life Cycle . *MBio.* 2019;10. doi:10.1128/mbio.01170-19

574 18. Arsic D, Guerin PM. Nutrient content of diet affects the signaling activity  
575 of the insulin/target of rapamycin/p70 S6 kinase pathway in the African  
576 malaria mosquito *Anopheles gambiae*. *J Insect Physiol.* 2008;54.  
577 doi:10.1016/j.jinsphys.2008.06.003


578

579

580

# Fernandes, Briquet et al Figure 1

A



B





Figure1


# Fernandes, Briquet et al Figure 2

**A**




bioRxiv preprint doi: <https://doi.org/10.1101/2020.07.13.200402>; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.


**C**



**D**



**E**



**F**





Figure2

# Fernandes, Briquet *et al* Figure 3

A



B





Figure3

# Fernandes, Briquet *et al* Figure 4

A



bioRxiv preprint doi: <https://doi.org/10.1101/2020.07.13.200402>; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

B





Figure4

# Fernandes, Briquet et al Figure 5

**A**



**B**






Figure5

# Fernandes, Briquet *et al* Figure 6


**A**




**B**



**C**



**D**



**E**




Figure6